ATG5 and pancreatic neoplasm: In GEM models of KRASG12D-driven pancreatic cancer, either genetic (silencing of ATG5 or ATG7) or pharmacological (hydroxychloroquine) inhibition of autophagy appears to block the progression of low-grade, pre-malignant pancreatic intraepithelial neoplasias (PanINs) to high-grade pancreatic ductal adenocarcinoma (PDA) [79].